The previous data indicate that PD‐L1 expression is limited in LCNEC cases (10%–20%), whereas both SCLC and NSCLC components exhibit high tumour mutation burden (TMB) compared to conventional NSCLC and SCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.